Roche announces that the European Commission has approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO), the third indication obtained for the product in the European Union.

This approval is based on data from two Phase III studies showing early and sustained improvements in vision not inferior to aflibercept, and robust retinal drying with Vabysmo.

The Swiss healthcare group adds that further longer-term data of up to 72 weeks show that up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months.

Copyright (c) 2024 CercleFinance.com. All rights reserved.